Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011.

Avanir intends to vigorously enforce its intellectual property rights relating to NUEDEXTA, which is protected by several patents covering the method of use of the product and its formulation. All of the currently issued patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Under the FDA's rules and regulations, if Avanir initiates a patent infringement suit to defend the patents identified in any Paragraph IV notice it receives within 45 days after its receipt of such notice, the FDA is prevented from approving the ANDA until the earlier of: (1) 30 months; (2) the expiration of the patents at issue; or (3) a decision in the infringement case that all of such patents are not infringed or invalid.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

About NUEDEXTA


'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... WARSAW, Ind., July 24, 2014 Zimmer Holdings, ... for the quarter ended June 30, 2014.  The Company ... increase of 1.2% reported and 0.9% constant currency over ... for the quarter were $1.03 reported and $1.49 adjusted, ... period. "The second quarter was marked ...
(Date:7/24/2014)... , July 24, 2014 ... today announced that it has been selected ... non-profit organization with membership representation from 19 ... subscription-based platform that will transform the way ... clinical trials. TransCelerate BioPharma Inc. is dedicated ...
(Date:7/23/2014)... -- Varian Medical Systems (NYSE: VAR ) today ... in the third quarter of fiscal year 2014.  Net ... share due to an approximately $8 million impairment charge ... in Augmenix, a privately-held company developing minimally invasive hydrogels ... the third quarter of fiscal year 2014, up 3 ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9
... NDA for Ondansetron Orally Dissolving Film StripBioAlliance to Resubmit ... Pharmaceuticals, the proprietary products division of a wholly owned ... PRX ), today provides an update on two of ... Strip On April 7, 2009, Strativa submitted a New ...
... April 7 Scientists at Schepens Eye Research Institute ... is essential to the health of blood vessels in ... dysfunction. These findings, published in the April 2 issue ... the prevention and treatment of diseases such as diabetic ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels 2Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels 3
(Date:7/24/2014)... Texas Physical Therapy Specialists ’ ... installation of the AlterG Anti-Gravity Treadmill , a ... to continue training stress-free while recovering from injury. , ... July 2014, uses technology created by NASA to enable ... 80% of the weight normally included in these activities. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 ... represents a rapidly expanding sector in the in-vitro ... specimen collection devices, new detection technologies, computers, and ... sensitivity, versatility, and speed. In addition to disease ... its benefits in patient stratification, drug regimen selection, ...
(Date:7/24/2014)... ReNewLifeCleansing.com was inspired by ReNew Life ... While waging her battle with poor health, she discovered ... her recovery. She became an expert on cleansing, detoxification, ... minerals, and other ingredients derived from nature help support ... waste and toxins for better overall health. , “Lately, ...
(Date:7/24/2014)... Skin management experts at FACE Skincare Medical Wellness ... the Geneo™ 3-in-1 Super Facial, specifically designed to increase ... large pores, leaving skin looking radiant. FACE is one ... treatment from Israel, and the first and only ... treatment. , This innovative treatment uses the unique ...
(Date:7/24/2014)... Crawford Technologies today announced the ... with AIIM, focusing on global trends in high-volume ... the survey indicated that even though organizations stated ... customer service, legal and regulatory compliance and historical ... exact facsimiles of these documents. , The survey ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Helps Patients Recover With AlterG Anti-Gravity Treadmill 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 4Health News:ReNew Life Launches New Educational Cleansing & Detox Website—ReNewLifeCleansing.com 2Health News:FACE Skincare Medical Wellness Debuts Exclusive 3-in-1 Facial Treatment in Michigan 2Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 2Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 3Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 4
... transplanted almost half of face taken from a brain dead donor ... from the lips, nose and chin was taken and transplanted to ... ,Doctors have clarified that the face the woman ... not resemble the donor’s face. ,If accepted the real ...
... international team of researchers has revealed that the inhalers ... chances of an attack.// Mathematical modeling techniques have been ... an asthma attack is likely to take place. The ... study. ,Silverman, professor of child health in the ...
... to make improvements in the services it provides children. ... ill should not be compelled to visit // hospitals for ... Department of Health which insists that individual needs must be ... at home like nurse led services. , It should ...
... been paying lesser attention to programs with regard to ... social development. The Social Development Research Group of the ... almost 600 students which revealed that tackling anti-social tendencies ... contributes towards better academic performance. ,The progress reported ...
... The application of anti-microbial coating over artificial implants such ... to reduce the infection rates following surgery. // This ... the health care cost and an improvement in the ... surgery, the implantable devices are prone for infection. In ...
... is all praise for the healthcare facilities available in India ... The surgery at the Ramaiah Memorial Hospital has cured her ... as she was unable to get the treatment on the ... her 5,000 pounds. The NHS in the UK has come ...
Cached Medicine News:Health News:Asthma Attacks May Be Triggered By Inhalers 2Health News:Anti-Microbial Coating For Use Over Biomedical Devices Developed 2Health News:Indian Healthcare Facilities Come In For Praise 2
The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Low-profile hand-held instruments....
Medicine Products: